Scholarlink

Background <p>Due to the difference of progression and therapeutic regimen of diabetic kidney disease (DKD) and non-diabetic kidney disease (NDKD), distinguishing DKD from NDKD is helpful to improve the prognosis of patients.</p> Objective <p>The aim of this study is to investigate the clinical value of soluble Tim-3 (sTim-3) in diabetes mellitus (DM) patients with chronic kidney disease (CKD).</p> Methods <p>In this study, a highly sensitive time-resolved fluorescence immunoassay was used to determine the serum sTim-3 levels in individuals. A total of 105 cases of DM patients with CKD (35 cases of DKD, 57 cases of NDKD, 13 cases of DKD plus NDKD) and 31 controls were quantified. The clinical value of sTim-3 in DM patients with CKD was analyzed.</p> Results <p>Serum sTim-3 levels in DKD patients (38.66, 29.83–52.09&#xa0;ng/mL) were significantly higher than those in NDKD patients (21.84, 16.57–31.71&#xa0;ng/mL; <i>p</i> &lt; 0.0001). DM patients with late stage CKD (G3 + G4) (37.00, 27.90–47.98&#xa0;ng/mL) had significantly higher sTim-3 levels than DM patients with early stage CKD (G1 + G2) (22.03, 16.61–35.30&#xa0;ng/mL; <i>p</i> = 0.0004). sTim-3 levels gradually increased with the degree of disease risk of DM with CKD. The combined detection of sTim-3 and diabetic retinopathy (AUC 0.8552, sensitivity 85.29%, specificity 82.76%) had a high value in distinguishing DKD from NDKD.</p> Conclusion <p>The level of sTim-3 shows value in distinguishing DKD from NDKD, with an elevated sTim-3 levels associated with impaired renal function. Combined detection of sTim-3 and diabetic retinopathy improves the ability to differentiate DKD from NDKD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum soluble Tim-3 can help distinguish diabetic kidney disease from non-diabetic kidney disease and is also correlated with the degree of renal damage

  • 期刊论文

  • 发表日期：

    2026年2月13日

查看全文
  • Jialong Wu,
  • Danqin Sun,
  • Meichun Chen,
  • Ting Shen,
  • Shangbin Kao,
  • Yuan Qin,
  • Xueqin Zhao,
  • Xiumei Zhou,
  • Juan Jin,
  • Biao Huang

摘要

Background

Due to the difference of progression and therapeutic regimen of diabetic kidney disease (DKD) and non-diabetic kidney disease (NDKD), distinguishing DKD from NDKD is helpful to improve the prognosis of patients.

Objective

The aim of this study is to investigate the clinical value of soluble Tim-3 (sTim-3) in diabetes mellitus (DM) patients with chronic kidney disease (CKD).

Methods

In this study, a highly sensitive time-resolved fluorescence immunoassay was used to determine the serum sTim-3 levels in individuals. A total of 105 cases of DM patients with CKD (35 cases of DKD, 57 cases of NDKD, 13 cases of DKD plus NDKD) and 31 controls were quantified. The clinical value of sTim-3 in DM patients with CKD was analyzed.

Results

Serum sTim-3 levels in DKD patients (38.66, 29.83–52.09 ng/mL) were significantly higher than those in NDKD patients (21.84, 16.57–31.71 ng/mL; p < 0.0001). DM patients with late stage CKD (G3 + G4) (37.00, 27.90–47.98 ng/mL) had significantly higher sTim-3 levels than DM patients with early stage CKD (G1 + G2) (22.03, 16.61–35.30 ng/mL; p = 0.0004). sTim-3 levels gradually increased with the degree of disease risk of DM with CKD. The combined detection of sTim-3 and diabetic retinopathy (AUC 0.8552, sensitivity 85.29%, specificity 82.76%) had a high value in distinguishing DKD from NDKD.

Conclusion

The level of sTim-3 shows value in distinguishing DKD from NDKD, with an elevated sTim-3 levels associated with impaired renal function. Combined detection of sTim-3 and diabetic retinopathy improves the ability to differentiate DKD from NDKD.